vs
Side-by-side financial comparison of Altimmune, Inc. (ALT) and SOPHiA GENETICS SA (SOPH). Click either name above to swap in a different company.
SOPHiA GENETICS SA is the larger business by last-quarter revenue ($47.4K vs $26.0K, roughly 1.8× Altimmune, Inc.). SOPHiA GENETICS SA produced more free cash flow last quarter ($-33.6K vs $-67.5M). Over the past eight quarters, Altimmune, Inc.'s revenue compounded faster (128.0% CAGR vs 45.1%).
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative immunotherapies, vaccines, and peptide-based therapies. Its pipeline covers infectious disease prevention, liver disease treatments, and metabolic disorder therapies, serving global biopharmaceutical and healthcare markets while advancing candidates through clinical trials.
Sophia Genetics SA is a Swiss-founded data-driven medicine software company with headquarters in Rolle, Switzerland and Boston, Massachusetts, as well as offices in France. It provides genomic and radiomic, and multimodal analysis for hospitals, laboratories, and biopharma institutions.
ALT vs SOPH — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $26.0K | $47.4K |
| Net Profit | — | — |
| Gross Margin | — | 67.1% |
| Operating Margin | — | -103.5% |
| Net Margin | — | — |
| Revenue YoY | 420.0% | — |
| Net Profit YoY | -18.0% | — |
| EPS (diluted) | — | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $26.0K | — | ||
| Q3 25 | $5.0K | $47.4K | ||
| Q2 25 | $5.0K | $15.8K | ||
| Q1 25 | $5.0K | $15.8K | ||
| Q4 24 | $5.0K | — | ||
| Q3 24 | $5.0K | $45.3K | ||
| Q2 24 | $5.0K | $29.0K | ||
| Q1 24 | $5.0K | $14.0K |
| Q4 25 | — | — | ||
| Q3 25 | $-19.0M | — | ||
| Q2 25 | $-22.1M | $-22.4M | ||
| Q1 25 | $-19.6M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-22.8M | — | ||
| Q2 24 | $-24.6M | $-15.2M | ||
| Q1 24 | $-24.4M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 67.1% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 65.9% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 68.4% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 69.4% |
| Q4 25 | — | — | ||
| Q3 25 | -417180.0% | -103.5% | ||
| Q2 25 | -458440.0% | -116978.7% | ||
| Q1 25 | -436300.0% | -118.9% | ||
| Q4 24 | — | — | ||
| Q3 24 | -495340.0% | -123.3% | ||
| Q2 24 | -534900.0% | -51705.7% | ||
| Q1 24 | -535880.0% | -138.1% |
| Q4 25 | — | — | ||
| Q3 25 | -380280.0% | — | ||
| Q2 25 | -442920.0% | -141789.0% | ||
| Q1 25 | -391500.0% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -456900.0% | — | ||
| Q2 24 | -492800.0% | -52353.5% | ||
| Q1 24 | -487880.0% | — |
| Q4 25 | — | — | ||
| Q3 25 | $-0.21 | — | ||
| Q2 25 | $-0.27 | $-0.33 | ||
| Q1 25 | $-0.26 | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-0.32 | — | ||
| Q2 24 | $-0.35 | $-0.23 | ||
| Q1 24 | $-0.34 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $273.5M | $80.2K |
| Total DebtLower is stronger | $34.3M | — |
| Stockholders' EquityBook value | $224.9M | $96.5K |
| Total Assets | $279.9M | $155.3K |
| Debt / EquityLower = less leverage | 0.15× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $273.5M | — | ||
| Q3 25 | $210.8M | $80.2K | ||
| Q2 25 | $183.1M | $94.8M | ||
| Q1 25 | $149.8M | $80.2K | ||
| Q4 24 | $131.9M | — | ||
| Q3 24 | $139.4M | $123.3K | ||
| Q2 24 | $164.9M | $105.4M | ||
| Q1 24 | $182.0M | $123.3K |
| Q4 25 | $34.3M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $224.9M | — | ||
| Q3 25 | $185.6M | $96.5K | ||
| Q2 25 | $161.4M | $76.7M | ||
| Q1 25 | $142.2M | $85.6M | ||
| Q4 24 | $123.5M | — | ||
| Q3 24 | $133.4M | $151.4K | ||
| Q2 24 | $152.5M | $121.4M | ||
| Q1 24 | $172.9M | $132.2M |
| Q4 25 | $279.9M | — | ||
| Q3 25 | $218.4M | $155.3K | ||
| Q2 25 | $190.3M | $177.6M | ||
| Q1 25 | $157.3M | $155.3K | ||
| Q4 24 | $139.3M | — | ||
| Q3 24 | $147.9M | $206.2K | ||
| Q2 24 | $173.3M | $181.1M | ||
| Q1 24 | $188.4M | $206.2K |
| Q4 25 | 0.15× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-67.5M | $-33.5K |
| Free Cash FlowOCF − Capex | $-67.5M | $-33.6K |
| FCF MarginFCF / Revenue | -259792.3% | -70.9% |
| Capex IntensityCapex / Revenue | 42.3% | 0.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-67.5M | — | ||
| Q3 25 | $-11.9M | $-33.5K | ||
| Q2 25 | $-19.4M | — | ||
| Q1 25 | $-16.8M | $-14.6K | ||
| Q4 24 | $-79.8M | — | ||
| Q3 24 | $-27.1M | $-39.9K | ||
| Q2 24 | $-18.1M | $-26.7K | ||
| Q1 24 | $-16.4M | $-15.7K |
| Q4 25 | $-67.5M | — | ||
| Q3 25 | — | $-33.6K | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-41.2K | ||
| Q2 24 | — | $-27.9K | ||
| Q1 24 | — | $-16.2K |
| Q4 25 | -259792.3% | — | ||
| Q3 25 | — | -70.9% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -91.0% | ||
| Q2 24 | — | -96.2% | ||
| Q1 24 | — | -115.8% |
| Q4 25 | 42.3% | — | ||
| Q3 25 | 0.0% | 0.4% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 3.0% | ||
| Q2 24 | — | 4.3% | ||
| Q1 24 | — | 3.6% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
